Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

notreload_ai Oct. 20 at 3:57 PM

$BOLT , $NAMS ... H.C. Wainwright initiates coverage on Bolt Biotherapeutics and NewAmsterdam Pharma with Buy ratings, highlighting innovative treatments in development. https://notreload.xyz/bolt-bio-newamsterdam-get-hc-wainwright-buy-ratings/

0 · Reply

Digger75 Oct. 20 at 1:04 PM

$NAMS looking at the order flow over the past few weeks someone was buying big chunks above 40.00 now it gets upgraded hmm

0 · Reply

JarvisFlow Oct. 20 at 10:46 AM

HC Wainwright & Co. has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 52.

1 · Reply

BioTechHealthX Oct. 19 at 6:19 AM

$NAMS NewAmsterdam Pharma rockets nearly 94% year-over-year as investors bet big on its late-stage cholesterol drug obicetrapib. https://biotechhealthx.com/biotech-news/newamsterdam-pharma-nams-soars-93-9-in-12-months/

0 · Reply

masonat Oct. 18 at 1:09 AM

$NAMS Alzheimer's biomarker data published. https://www.sciencedirect.com/science/article/pii/S227458072500336X

2 · Reply

newfguy Oct. 17 at 3:31 PM

$NAMS the pause that refreshes

0 · Reply

JarvisFlow Oct. 17 at 3:28 PM

Citigroup updates rating for NewAmsterdam Pharma Co ( $NAMS ) to Buy, target set at 42 → 50.

0 · Reply

masonat Oct. 16 at 10:18 PM

$NAMS The last time NAMS was randomly down 10%...one whole month ago. What happened after? Oh. Almost like you can't make any conclusions based on a single day's movement.

0 · Reply

___IFindKarma___ Oct. 16 at 10:10 PM

$NAMS Another $28 to go. Down.

0 · Reply

YoloAlfred Oct. 16 at 9:51 PM

$NAMS It gets much worse.....

0 · Reply

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 3, 2025, 10:22 PM EDT - 7 weeks ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 21, 2025, 2:41 AM EDT - 2 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 18, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 6, 2025, 7:00 AM EDT - 2 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Jul 30, 2025, 8:25 AM EDT - 3 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 9, 2025, 7:00 AM EDT - 4 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

May 27, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 14, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2025, 7:15 AM EDT - 6 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

May 2, 2025, 4:01 PM EDT - 6 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Mar 31, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 8 months ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 8 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 8 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 8 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Dec 13, 2024, 5:16 PM EST - 11 months ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 11 months ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 11 months ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 6:55 AM EST - 11 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

Dec 10, 2024, 4:34 PM EST - 11 months ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 11 months ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 11 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Feb 28, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 13, 2024, 10:40 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 1, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Nov 13, 2023, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Oct 23, 2023, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Oct 17, 2023, 3:00 AM EDT - 2 years ago

Tessellate BIO Emerges from Stealth

REPL

Oct 2, 2023, 9:26 PM EDT - 2 years ago

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

notreload_ai Oct. 20 at 3:57 PM

0 · Reply

Digger75 Oct. 20 at 1:04 PM

$NAMS looking at the order flow over the past few weeks someone was buying big chunks above 40.00 now it gets upgraded hmm

0 · Reply

JarvisFlow Oct. 20 at 10:46 AM

HC Wainwright & Co. has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 52.

1 · Reply

BioTechHealthX Oct. 19 at 6:19 AM

0 · Reply

masonat Oct. 18 at 1:09 AM

$NAMS Alzheimer's biomarker data published. https://www.sciencedirect.com/science/article/pii/S227458072500336X

2 · Reply

newfguy Oct. 17 at 3:31 PM

$NAMS the pause that refreshes

0 · Reply

JarvisFlow Oct. 17 at 3:28 PM

Citigroup updates rating for NewAmsterdam Pharma Co ( $NAMS ) to Buy, target set at 42 → 50.

0 · Reply

masonat Oct. 16 at 10:18 PM

$NAMS The last time NAMS was randomly down 10%...one whole month ago. What happened after? Oh. Almost like you can't make any conclusions based on a single day's movement.

0 · Reply

___IFindKarma___ Oct. 16 at 10:10 PM

$NAMS Another $28 to go. Down.

0 · Reply

YoloAlfred Oct. 16 at 9:51 PM

$NAMS It gets much worse.....

0 · Reply

tttggg Oct. 16 at 8:31 PM

$NAMS well… today’s option flow quite bearish…. No idea what’s going on…..

0 · Reply

omar_progressivetrading Oct. 16 at 7:37 PM

$NAMS Someone tell @NewFguy - TTIIMMMBBBEERRR! 🫡🌓 Zealot! 🫠

2 · Reply

djohnson591 Oct. 16 at 7:31 PM

$ESPR We told these guys at $NAMS what was coming.

4 · Reply

newfguy Oct. 16 at 5:19 PM

$NAMS BTFD

0 · Reply

RunnerSignals Oct. 15 at 6:00 PM

wild ride alert $INV $ORGN $MOBX $PHAT $NAMS went full rollercoaster today with big intraday swings

0 · Reply

Heliosphere Oct. 15 at 4:48 PM

$ESPR $NAMS Let’s care about us! We are not on cloud9! Let them enjoy for now

0 · Reply

fortyeight Oct. 15 at 4:43 PM

$ESPR Shorts are piling into $NAMS, a rug pull is coming.

3 · Reply

prettyinscarlet Oct. 15 at 4:04 PM

$NAMS Sweet sweet trading chart. I've been long since $17. Reached my target price already, but it looks like there is plenty juice left to squeeze with the upcoming acquisition. Loaded up on calls too

0 · Reply

BioTechHealthX Oct. 15 at 12:49 PM

0 · Reply

lsb1201030758 Oct. 14 at 6:17 PM

$NAMS Nobody writes anything about this winner that has doubled in the last 3 months.

1 · Reply

newfguy Oct. 13 at 11:56 PM

$NAMS $40 AH. sweet

0 · Reply

thehivemindfund Oct. 13 at 10:49 PM

$NAMS What an ugly day. Price did a symmetrical round trip - rare "selling at top" signal. My puts are locked and loaded.

2 · Reply

Market Cap	4.09B
Revenue (ttm)	45.56M
Net Income (ttm)	-241.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-530.29%
Debt to Equity Ratio	0.00

Volume	746,400
Avg Vol	1,113,660
Day's Range	N/A - N/A
Shares Out	112.63M
Stochastic %K	19%
Beta	0.02
Analysts	Strong Sell
Price Target	$42.42